Eli Lilly’s market capitalisation hit the $1tn mark in the past week, becoming the first healthcare company in the world to ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

Eli Lilly became the first healthcare company to hit a $1 trillion valuation (briefly on Nov. 21) MONDAY, Nov. 24, 2025 ...

Novo Nordisk said an older version of its weight-loss drug semaglutide failed to meet its main goal in late-stage trials ...

Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding ...

Experts studying results from a clinical trial say other benefits seen with the medication, such as reduced blood pressure and lower levels of 'bad' cholesterol, also go into reverse upon stopping the ...

Dual glucagon (GCG) and GLP-1 agonist mazdutide is already approved for both type 2 diabetes and obesity in China at doses ...

But one of the more anticipated studies exploring how they impact Alzheimer’s disease has found no meaningful effect, Novo ...

Eli Lilly has hit $1 trillion in market value, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

Eli Lilly surged into a rarefied tier of corporate giants on November 21, becoming the first pharmaceutical company in history to reach a US$1 trillion market valuation ...